钱晓华, 沈洪波, 陈坤, 黄慧嫦, 张莉, 孙俪燕, 章影. HIV感染者接种23价肺炎链球菌多糖疫苗的免疫效果[J]. 上海预防医学, 2021, 33(2): 136-140. DOI: 10.19428/j.cnki.sjpm.2021.20314
引用本文: 钱晓华, 沈洪波, 陈坤, 黄慧嫦, 张莉, 孙俪燕, 章影. HIV感染者接种23价肺炎链球菌多糖疫苗的免疫效果[J]. 上海预防医学, 2021, 33(2): 136-140. DOI: 10.19428/j.cnki.sjpm.2021.20314
shu
QIAN Xiao-hua, SHEN Hong-bo, CHEN Kun, HUANG Hui-chang, ZHANG Li, SUN Li-yan, ZHANG Ying. Immune response after inoculation with PPV23 in HIV-infected adults[J]. Shanghai Journal of Preventive Medicine, 2021, 33(2): 136-140. DOI: 10.19428/j.cnki.sjpm.2021.20314
Citation: QIAN Xiao-hua, SHEN Hong-bo, CHEN Kun, HUANG Hui-chang, ZHANG Li, SUN Li-yan, ZHANG Ying. Immune response after inoculation with PPV23 in HIV-infected adults[J]. Shanghai Journal of Preventive Medicine, 2021, 33(2): 136-140. DOI: 10.19428/j.cnki.sjpm.2021.20314
shu

HIV感染者接种23价肺炎链球菌多糖疫苗的免疫效果

Immune response after inoculation with PPV23 in HIV-infected adults

    摘要
  • 摘要:
    目的分析人类免疫缺陷病毒（HIV）感染者接种23价肺炎链球菌多糖疫苗（PPV23）后功能性抗体和社区获得性肺炎（CAP）发病保护效果。
    方法2015年在上海市虹口区随机选择成人HIV感染者63人，采集接种PPV23前后1个月的血标本，用肺炎链球菌荚膜多糖特异性抗体调理吞噬杀菌试验（OPA）检测4个血清型（19F、19A、23F、6B）肺炎链球菌的功能性抗体；同时调查人群接种PPV23后的CAP发病情况。
    结果HIV感染者接种PPV23后1个月的4个血清型OPA抗体几何平均滴度（GMT）显著高于接种前；HIV感染者接种后4个血清型OPA抗体≥3倍增长率分别为50% ~ 91.67%；HIV感染者接种PPV23后与接种前自身和对照组比较，接种后2年的肺炎发病保护率均为100%。接受高效抗逆转录病毒治疗（HAART）或CD4+计数≥300/μL的HIV感染者接种PPV23后能较好地产生OPA抗体，并获得对社区获得性肺炎（CAP）的保护。
    结论建议对基本情况良好的HIV感染者常规接种PPV23。

     

    Abstract:
    ObjectiveTo study the functional antibody and protection effect against pneumonia disease after inoculation with PPV23 in HIV-infected adults.
    MethodsIn 2015, 63 HIV-infected adults were randomly selected in Hongkou District of Shanghai, and blood samples were collected before and one month after the inoculation of PPV23.Functional antibodies against 4 serotypes (19F, 19A, 23F, 6B) of Streptococcus pneumoniae were detected by opsonophagocyitosis killing assay (OPA).The incidence of pneumonia after PPV23 inoculation was also determined.
    ResultsThe GMT of OPA antibodies against 4 serotypes 1 month after inoculation with PPV23 was significantly higher than that before inoculation in HIV-infected subjects.After inoculation, the triple growth rates of OPA antibodies against 4 serotypes in HIV-infected subjects were 50%-91.67%.The protection rate against pneumonia was 100% in 2 years after PPV23 inoculation in HIV-infected subjects when compared with same group before inoculation as well as the control group.The HIV-infected patients who received highly active antiretroviral therapy (HAART) or had CD4 count of≥300/μL showed better response in production of OPA antibodies and obtained protection against community-acquired pneumonia (CAP) after receiving PPV23.
    ConclusionRoutine vaccination of PPV23 is recommended for HIV-infected patients with good basic conditions.

     

    • HTML全文
    • 参考文献(31)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回